These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

585 related articles for article (PubMed ID: 29579717)

  • 1. Pseudoprogression and hyperprogression after checkpoint blockade.
    Wang Q; Gao J; Wu X
    Int Immunopharmacol; 2018 May; 58():125-135. PubMed ID: 29579717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
    Failing JJ; Dudek OA; Marin Acevedo JA; Chirila RM; Dong H; Markovic SN; Dronca RS
    Future Oncol; 2019 Aug; 15(22):2645-2656. PubMed ID: 31298573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.
    Kato S; Goodman A; Walavalkar V; Barkauskas DA; Sharabi A; Kurzrock R
    Clin Cancer Res; 2017 Aug; 23(15):4242-4250. PubMed ID: 28351930
    [No Abstract]   [Full Text] [Related]  

  • 4. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 6. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
    Pitt JM; Vétizou M; Daillère R; Roberti MP; Yamazaki T; Routy B; Lepage P; Boneca IG; Chamaillard M; Kroemer G; Zitvogel L
    Immunity; 2016 Jun; 44(6):1255-69. PubMed ID: 27332730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression.
    Šmahel M
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28635644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Challenges of Immune Checkpoint Inhibitors.
    de Miguel M; Calvo E
    Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for metastatic urothelial carcinoma: status quo and the future.
    Necchi A; Rink M; Giannatempo P; Raggi D; Xylinas E
    Curr Opin Urol; 2018 Jan; 28(1):1-7. PubMed ID: 29028766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperprogression under Immunotherapy.
    Frelaut M; Le Tourneau C; Borcoman E
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R; Merghoub T; Wolchok JD
    Cancer Cell; 2018 Apr; 33(4):581-598. PubMed ID: 29634946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
    Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
    World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment.
    Wang Q; Wu X
    Int Immunopharmacol; 2017 May; 46():210-219. PubMed ID: 28324831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.